- Home
- RYDE vs ENSC Comparison
RYDE vs ENSC Comparison
Compare RYDE & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- ENSC
- Stock Information
- Founded
- RYDE 2014
- ENSC 2003
- Country
- RYDE Singapore
- ENSC United States
- Employees
- RYDE N/A
- ENSC N/A
- Industry
- RYDE
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- ENSC Health Care
- Exchange
- RYDE NYSE
- ENSC Nasdaq
- Market Cap
- RYDE 5.2M
- ENSC 4.9M
- IPO Year
- RYDE 2024
- ENSC N/A
- Fundamental
- Price
- RYDE $0.36
- ENSC $2.16
- Analyst Decision
- RYDE
- ENSC
- Analyst Count
- RYDE 0
- ENSC 0
- Target Price
- RYDE N/A
- ENSC N/A
- AVG Volume (30 Days)
- RYDE 29.7M
- ENSC 53.2K
- Earning Date
- RYDE 05-02-2025
- ENSC 08-13-2025
- Dividend Yield
- RYDE N/A
- ENSC N/A
- EPS Growth
- RYDE N/A
- ENSC N/A
- EPS
- RYDE N/A
- ENSC N/A
- Revenue
- RYDE $6,557,978.00
- ENSC $6,224,081.00
- Revenue This Year
- RYDE $21.13
- ENSC N/A
- Revenue Next Year
- RYDE $13.43
- ENSC $1,381.48
- P/E Ratio
- RYDE N/A
- ENSC N/A
- Revenue Growth
- RYDE 3.27
- ENSC 256.35
- 52 Week Low
- RYDE $0.16
- ENSC $1.62
- 52 Week High
- RYDE $22.49
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- ENSC 46.61
- Support Level
- RYDE N/A
- ENSC $1.97
- Resistance Level
- RYDE N/A
- ENSC $2.40
- Average True Range (ATR)
- RYDE 0.00
- ENSC 0.16
- MACD
- RYDE 0.00
- ENSC 0.00
- Stochastic Oscillator
- RYDE 0.00
- ENSC 44.19
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.